PG
RXRX icon

Proffitt & Goodson’s Recursion Pharmaceuticals RXRX Stock Holding History

Proffitt & Goodson’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-657
Closed -$3.48K – 274
2025
Q1 		$3.48K Buy
+657
New +$4.79K ﹤0.01% 233

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Proffitt & Goodson's RXRX Position: Q2 2025 in Review

Proffitt & Goodson sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 657 shares — an estimated $3.48K sold.

Proffitt & Goodson first reported a position in RXRX in Q1 2025 and held it in 1 quarter. The position peaked at $3.48K in Q1 2025. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Proffitt & Goodson reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Proffitt & Goodson sold 657 Recursion Pharmaceuticals shares in Q2 2025, an estimated $3.48K.
  • Proffitt & Goodson first reported a position in Recursion Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Proffitt & Goodson's Recursion Pharmaceuticals position peaked at $3.48K in Q1 2025.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Proffitt & Goodson's 13F filing for Q2 2025, filed 23 Jul 2025.